Table 1. Characteristics of the 1,489 patients treated on an anti-VEGF/R-based phase I trial.
| AYA (15–39 y) | Middle age (40–64 y) | Older adults (65+y) | |
|---|---|---|---|
| n | 220 (15%) | 991 (67%) | 278 (18%) |
| Age, median, years | 32.6 | 53.8 | 68.9 |
| Age, range, years | 15.4–39.9 | 40.0–64.9 | 65.0–86.3 |
| Gender | |||
| Female | 148 (67%) | 548 (55%) | 127 (46%) |
| Male | 72 (33%) | 443 (45%) | 151 (54%) |
| #prior therapies, median (range) | 3 (0–15) | 3 (0–13) | 3 (0–13) |
| Primary cancer | |||
| Breast | 20 (9%) | 95 (10%) | 14 (5%) |
| Endocrine | 17 (8%) | 60 (6%) | 13 (5%) |
| Gastrointestinal | 35 (16%) | 306 (31%) | 97 (35%) |
| Genitourinary | 7 (3%) | 81 (8%) | 20 (7%) |
| Gynecologic | 41 (19%) | 160 (16%) | 34 (12%) |
| Melanoma | 25 (11%) | 90 (9%) | 30 (11%) |
| Other | 5 (2%) | 20 (2%) | 17 (6%) |
| Sarcoma | 39 (18%) | 46 (5%) | 10 (4%) |
| Thoracic/Head/Neck | 31 (14%) | 133 (13%) | 43 (15%) |